Nuvectis Pharma, Inc. - Common Stock — Statistiques financières trimestrielles (NASDAQ:NVCT) | MetaTrader

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Flux de trésorerie liés aux activités d'exploitation -2.46 M-4.17 M-3.37 M-4.49 M-3.97 M-6.51 M -18.35 M Flux de trésorerie liés aux activités d'investissement 000000 0 Flux de trésorerie liés aux activités de financement 3.83 M15.51 M296 K13.14 M166 K7 000 13.61 M Flux de trésorerie disponible -2.46 M-4.17 M-3.37 M-4.49 M-3.97 M-6.51 M -18.35 M

Nouvelles

Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

Nuvectis initiates phase 1b trial combining NXP900 with osimertinib

Notation de l’action Nuvectis Pharma réitérée à l’achat par H.C. Wainwright

Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright maintient sa recommandation d’achat sur Nuvectis Pharma avec un objectif de 10$

H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target

Nuvectis Pharma adds former Intra-Cellular exec to board of directors

Nuvectis initiates phase 1b program for cancer drug NXP900

Nuvectis (NVCT) Q2 Loss Widens 43%

Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright

Nuvectis halts NXP800 development for ovarian cancer, shifts focus